2023 World Conference on Lung Cancer (Posters)-P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION - PDF(Abstract)

Back to course

Pdf Summary

This presentation, titled "Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION," discusses the efficacy and safety of tepotinib, a MET tyrosine kinase inhibitor, in Asian patients with MET exon 14 skipping NSCLC. The study was conducted as part of the VISION trial, which included a total of 313 patients.<br /><br />The results showed that tepotinib demonstrated durable clinical activity, with an objective response rate (ORR) of 56.6% in Asian patients. The median duration of response (DOR) was 18.5 months, and the median progression-free survival (PFS) and overall survival (OS) were 13.8 months and 25.5 months, respectively. These results were consistent across different treatment lines, including treatment-naïve and previously treated patients.<br /><br />The study also found that tepotinib had a manageable safety profile in Asian patients. Treatment-related adverse events (TRAEs) were reported in 95.3% of patients, with peripheral edema, blood creatinine increase, and diarrhea being the most common TRAEs.<br /><br />Furthermore, the study showed that the health-related quality of life (HRQoL) of patients remained stable during treatment, as measured by various scales.<br /><br />Overall, tepotinib demonstrated robust and durable efficacy in Asian patients with MET exon 14 skipping NSCLC, particularly when used as a first-line treatment. The findings suggest that tepotinib could be a valuable treatment option for this patient population.

Asset Subtitle

Myung-Ju Ahn

Meta Tag

Speaker Myung-Ju Ahn

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

Tepotinib

Asian patients

MET exon 14 skipping

Non-small Cell Lung Cancer

NSCLC

efficacy

safety

VISION trial

objective response rate

duration of response